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Abstract
Background: The use of prostate cancer screening tools that take into account relevant prebiopsy information (ie, risk calculators)
is recommended as a way of determining the risk of cancer and the subsequent need for a prostate biopsy. This has the potential
to limit prostate cancer overdiagnosis and subsequent overtreatment. mHealth apps are gaining traction in urological practice and
are used by both practitioners and patients for a variety of purposes.
Objective: The impetus of the study was to design, develop, and assess a smartphone app for prostate cancer screening, based
on the Rotterdam Prostate Cancer Risk Calculator (RPCRC).
Methods: The results of the Rotterdam arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC)
study were used to elaborate several algorithms that allowed the risk of prostate cancer to be estimated. A step-by-step workflow
was established to ensure that depending on the available clinical information the most complete risk model of the RPCRC was
used. The user interface was designed and then the app was developed as a native app for iOS. The usability of the app was
assessed using the Post-Study System Usability Questionnaire (PSSUQ) developed by IBM, in a group of 92 participants comprising
urologists, general practitioners, and medical students.
Results: A total of 11 questions were built into the app, and, depending on the answers, one of the different algorithms of the
RPCRC could be used to predict the risk of prostate cancer and of clinically significant prostate cancer (Gleason score ≥7 and
clinical stage >T2b). The system usefulness, information quality, and interface quality scores were high—92% (27.7/30), 87%
(26.2/30), and 89% (13.4/15), respectively. No usability problems were identified.
Conclusions: The RPCRC app is helpful in predicting the risk of prostate cancer and, even more importantly, clinically significant
prostate cancer. Its algorithms have been externally validated before and the usability score shows the app’s interface is well
designed. Further usability testing is required in different populations to verify these results and ensure that it is easy to use, to
warrant a broad appeal, and to provide better patient care.
(JMIR Cancer 2017;3(1):e1)   doi:10.2196/cancer.6750
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Introduction
Prostate cancer is a serious health issue, accounting for 14% of
all new cancers and 6% of total cancer deaths in men worldwide
[1]. With the expected increase in life expectancy, the disease’s
burden is projected to increase substantially [2]. However,
neither the optimal balance between screening intensity and the
risk of overdiagnosis (ie, detecting indolent disease) nor the
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ideal prostate cancer screening test or combination of tests have
been determined [3].
To address these issues, screening trials were initiated. Recently,
the third analysis of the European Randomized Study of
Screening for Prostate Cancer (ERSPC), the world’s largest
prostate cancer screening study, has been published. Currently,
with more than 13 years of follow-up, the updated results show
a stable relative benefit of screening (relative risk=0.79, ie, a
21% prostate cancer mortality reduction in favor of screening)
but a still increasing absolute benefit [3]. The recently published
findings show that to avoid one prostate cancer death, 781 men
would need to be invited to screening and 27 additional prostate
cancer cases will be diagnosed compared with no screening,
both decreasing as compared with previous reports with shorter
follow-up [3]. In summary, the number needed to screen and
to treat to avoid one death from prostate cancer is decreasing
and is now lower than the reported number needed to screen in
trials for breast cancer [4].
Currently, the decision to perform a prostate biopsy is mostly
based on the outcome of the serum prostate-specific antigen
(PSA) test. However, the serum PSA level can increase in many
situations, including benign (eg, benign prostatic hyperplasia)
and inflammatory conditions (eg, acute prostatitis). Moreover,
the optimal cutoff value has not yet been established [5].
Leveraging the decision of performing prostate biopsy solely
on the PSA value, using a PSA value greater than 3.0 ng/mL as
indication for Bx, resulted in 76% negative biopsy results [6].
Conversely, using a higher PSA threshold can neglect prostate
cancer cases [7]. To address this lack of specificity, it is
recommended that the PSA value should be combined with
other relevant patient characteristics, using so-called risk
calculators [2]. Even though many are available, currently it is
not possible to provide a clear recommendation about which
one to use in which situation (eg, first prostate biopsy, repeated
prostate biopsy, patient with small prostate) because there are
no direct head-to-head comparisons [8]. One scientifically sound
and extensively validated risk calculator is the Rotterdam
Prostate Cancer Risk Calculator (RPCRC), based on the ERSPC
Rotterdam data [9].
The RPCRC predicts the risk of a biopsy-detectable prostate
cancer and also of potentially high-risk prostate cancer, defined
as Gleason score ≥7 and clinical stage >T2b. This has important
clinical implications as a way of decreasing overdiagnosis and
overtreatment [3]. The different RPCRC algorithms provide an
increasingly accurate risk estimation (ie, adding variables to the
model increases its area under the curve, AUC). The algorithm
uses information on PSA level, previous negative prostate
biopsy, digital rectal examination (DRE) findings, prostate
volume measurement, and transrectal ultrasonography (TRUS)
findings. Additionally, the Prostate Health Index (phi), which
aggregates the results from the Hybritech PSA, free PSA, and
p2PSA (the [-2] form of proPSA), can also be used to further
stratify prostate cancer risk [10]. All these different prediction
models are available on the website of the Prostate Cancer
Research Foundation (Figure 1) [11].
At present, mobile health (mHealth), the delivery of health care
services via mobile communication devices, is a growing trend
with more than 160,000 medical apps available, and the number
is expected to grow even further, expedited by the ubiquitous
presence of mobile phones and the continuous improvements
in hardware and software [12,13]. To increase its usability and
accessibility, the originally Web-based RPCRC [11] has been
redesigned as an app, which has several benefits for the user.
Even though the app uses the same algorithms as the available
Web-based risk calculators [11], the app’s proprietary
step-by-step workflow ensures that, depending on the available
information, the most complete algorithm is always used. In
contrast, the website user has to initially choose a specific
RPCRC, which may not be the most comprehensive available
and inadvertently dismiss known clinical data.
Another strength of the app is that the calculations are performed
in the user’s mobile phone (ie, it works offline), which ensures
a safe user experience, bypassing issues with website blocking
(eg, some facilities constrain Internet access) and with
infrastructure and Internet service providers (eg, slow intranet
or low-speed Internet access).
Several studies have shown that mHealth was well received by
users, including health care professionals and patients, in both
urban and rural settings. Some examples include the use of
mobile phone–based guidance for rural health providers in Tamil
Nadu, India [14], and the use of a gestational diabetes app by
pregnant women in Oxford, United Kingdom [15]. Moreover,
it has been documented not only in young adults [16], but also
in older adults—both had a high degree of acceptance of apps
that promoted physical activity [17].
The aim of this study was to design and develop a mobile phone
app for prostate cancer screening, based on the RPCRC
algorithms. Moreover, we sought to evaluate the usability of
the developed app using IBM’s Post-Study System Usability
Questionnaire (PSSUQ) [18].
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Figure 1. Screenshot of the Prostate Cancer Research Foundation website showing the prostate cancer risk calculators.
Methods
This study was structured according to the standard life cycle
of system development: analysis, design, implementation, and
evaluation, as shown in Figure 2.
System Analysis
Knowledge and functional requirements for system
implementation were assessed.
Knowledge Requirements
All risk calculator algorithms used in the app were developed
based on the Rotterdam arm of the ERSPC, using the clinical
data and prostate biopsy outcome from 3624 previously
unscreened men and 2896 men with previous negative prostate
biopsy. The following 4 models were built, with cumulative
clinical information:
• Model 1—PSA alone;
• Model 2—PSA and DRE (normal/abnormal);
• Model 3—PSA, DRE (normal/abnormal) and DRE-assessed
volume;
• Model 4—PSA, DRE (normal/abnormal), TRUS
(normal/abnormal), and TRUS-assessed volume.
The predictive capability of the models within the RPCRC app
were assessed in terms of discrimination (C statistic) for
predicting the probability of both prostate cancer on biopsy and
serious prostate cancer (defined as >T2b and Gleason score ≥7)
[19]. Further details about the construction and the validation
of the RPCRC algorithms have been previously published [19].
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Figure 2. Study outline and research procedure. PSSUQ: Post-Study System Usability Questionnaire.
Functional Requirements
The system’s functional requirements were based on the
available risk calculator algorithms that were developed by the
Rotterdam ERSPC. To improve the RPCRC app usability, a
unique decision tree was devised, with a multistep approach, to
gather available clinical information: previous negative prostate
biopsy, PSA value, DRE evaluation, TRUS evaluation, and phi
value.
System Design
The app’s user interface was designed to ensure the best possible
experience, according to Apple’s design guidelines. The
interface was based on the RPCRC decision tree, taking into
account the clarity and ease of use, and was designed using the
GNU Image Manipulation Program (GIMP).
System Implementation
To ensure the best performance, a native iOS version was
developed using Apple’s Xcode (Apple Inc), an integrated
development environment that comprises a suite of software
development tools, including debugging functions.
System Usability Evaluation
Usability is defined as the measure of the ease with which a
system can be learned and used, including its safety,
effectiveness, and efficiency [20]. Usability is also a measure
of the effectiveness of the interaction between humans and
computer systems (ie, how do users perform tasks in the system)
[21]. The usability of the RPCRC app was evaluated using
IBM’s PSSUQ, which is currently in its third revision and
consists of 3 domains: system usefulness, information quality,
and interface quality [18]. These 3 domains cover 16 questions,
rated on a Likert scale from 1 (I strongly disagree) to 5 (I
strongly agree; Table 1). In addition, users also had the option
to write their own comments. The PSSUQ was chosen because
it is a popular usability testing instrument that was validated
and showed discriminative validity, discerning applications with
recognizably different quality [22]. Moreover, it has been used
in several other mHealth studies [16,23-25].
Urologists, medical students, and general practitioners (GPs)
were selected as end users; GPs were included because they are
the first gatekeepers for prostate cancer screening, making the
decision of whether or not to refer the patient to a urologist.
Medical students’ evaluation is pertinent because they will be
the urologists and GPs of tomorrow. An invitation to participate
in the study was sent via email.
For the quantitative measurements (baseline characteristics,
PSSUQ), means and standard deviations were calculated using
software package IBM SPSS v20 (IBM Corporation).
Results
System Analysis
Knowledge Requirements
All risk calculator algorithms used in the app were developed
based on the Rotterdam arm of the ERSPC, using the clinical
data and prostate biopsy outcome from 3624 previously
unscreened men and 2896 men with previous negative prostate
biopsy [19].
In the original previously unscreened men, applying model 1
to model 4 resulted in AUCs from 0.69 to 0.79, respectively,
for predicting prostate cancer and from 0.74 to 0.86,
respectively, for predicting serious prostate cancer. In the
previously screened group (men with at least one previous
negative prostate biopsy), applying the same models, AUCs
ranged from 0.62 to 0.69 for predicting prostate cancer and from
0.72 to 0.81 for predicting serious prostate cancer [19].
Several related papers that validate the algorithm of the RPCRC
in different cohorts and compare the RPCRC with other
calculators have been previously published, with good
performance in the various settings [26-33].
JMIR Cancer 2017 | vol. 3 | iss. 1 | e1 | p.4http://cancer.jmir.org/2017/1/e1/
(page number not for citation purposes)
Pereira-Azevedo et alJMIR CANCER
XSL•FO
RenderX
Functional Requirements
A unique decision tree was designed to ensure the app would
always use the most powerful risk calculator model, depending
on the available information (Figure 3). This ensures that the
most significant available data is used in the most complete
algorithm to compute with greater reliability the probability of
a positive prostate biopsy and the risk of aggressive prostate
cancer.
System Design
The app design can be divided into 6 interface categories:
disclaimer, question, explanation, language, results, and about
(Figure 4). The disclaimer must be accepted by the user before
using the app. A total of 11 questions were built into the app,
and, depending on the answers, one of the different algorithms
could be used to predict the risk of prostate cancer and of
significant prostate cancer. All question interfaces are designed
in a similar way. For every question, there is an interface with
an explanation of the question. The results (ie, risk of prostate
cancer and risk of aggressive prostate cancer) are shown in
numerical (percentage) and graphic forms. The “about” screen
details the scientific background of the risk calculators and lists
all contributions. The user also has the option to choose the
default language: Chinese, Dutch, English, German, Portuguese,
and Spanish.
Figure 3. The Rotterdam Prostate Cancer Risk Calculator decision tree. PSA: prostate-specific antigen; DRE: digital rectal examination; phi: Prostate
Health Index.
System Implementation
The debugging of the app was performed within the Apple
Xcode environment. All code errors were identified in a
step-by-step approach, through the use of the intrinsic debugging
tools, and were corrected according to Apple’s guidelines.
The functionalities of the app were assessed in various devices,
namely, mobile phones and tablets, in the usability evaluation
stage. Care was taken to ensure a consistent user experience
across all devices.
System Usability Evaluation
A total of 92 participants evaluated the usability of the app
(response rate = 11%), among whom 28 (30%) were urologists,
29 (32%) were medical students, and 35 (38%) were GPs. The
mean age of participants was 31 years and 62% were female.
The calculated mean and standard deviation of the PSSUQ 16
questions are presented in Table 1. “It was simple to use this
application” and “It was easy to learn to use this application”
had the highest rating among the 16 items, with 4.80 out of 5
possible points.
The final scores of the 3 domains evaluated (ie, system
usefulness, information quality, and interface quality) are
presented in Table 2. The highest score (92%) was reported for
system usefulness, and information quality got the lowest score
(87%). These results show that the participants were, overall,
satisfied with the usability of the app.
Figure 5 shows the percentage of actual scores given by
urologists, GPs, and medical students for system usefulness,
information quality, and interface quality. The highest score
was given for the system usefulness category by urologists.
JMIR Cancer 2017 | vol. 3 | iss. 1 | e1 | p.5http://cancer.jmir.org/2017/1/e1/
(page number not for citation purposes)
Pereira-Azevedo et alJMIR CANCER
XSL•FO
RenderX
Figure 4. Screenshots of the Rotterdam Prostate Cancer Risk Calculator app, showing “About,” “Disclaimer,” “Explanation,” “Question,” “Results,”
and “Language” screens.
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Table 1. Means and standard deviations of the Post-Study System Usability Questionnaire result.
SDMeanItemNo.Category
0.5574.67Overall, I am satisfied with how easy it is to use this application1System usefulness
0.3994.80It was simple to use this application2
0.6014.53I was able to complete the tasks and scenarios quickly using this ap-
plication
3
0.7474.55I felt comfortable using this application4
0.4264.80It was easy to learn to use this application5
0.9054.34I believe I could become productive quickly using this application6
1.3983.85The application gave error messages that clearly told me how to fix
problems
7Information quality
1.0674.16Whenever I made a mistake using the application, I could recover
easily and quickly
8
0.7014.43The information (such as on-line help, on-screen messages and other
documentation) provided with this application was clear
9
0.6544.47It was easy to find the information I needed10
0.6734.52The information was effective in helping me complete the tasks and
scenarios
11
0.4774.76The organization of information on the application screens was clear12
0.7894.57The interface of this application was pleasant13Interface quality
0.8194.51I liked using the interface of this application14
1.0644.29This application has all the functions and capabilities I expected it to
have
15
0.8804.42Overall, I am satisfied with this application16Overall
0.8324.48Total
Table 2. Scores per evaluation category of the Post-Study System Usability Questionnaire.
% Actual scorePossible scoreActual scoreItem category
923027.7System usefulness
873026.2Information quality
891513.4Interface quality
JMIR Cancer 2017 | vol. 3 | iss. 1 | e1 | p.7http://cancer.jmir.org/2017/1/e1/
(page number not for citation purposes)
Pereira-Azevedo et alJMIR CANCER
XSL•FO
RenderX
Figure 5. Percentage of actual score per item category and occupation of participants. GP: general practitioner.
Discussion
Principal Findings
Risk calculators are increasingly being used to stratify men at
risk of prostate cancer. The RPCRC, previously only available
digitally on the website [11], was based on the Rotterdam arm
of the ERSPC, which started in 1993 in Europe to study the
feasibility of population-based screening for prostate cancer
and its effect on mortality [34]. This new app is publicly
available on the Apple App Store [35].
To facilitate its use in clinical practice, we decided to create an
mHealth version using the RPCRC algorithms. However, to
simplify its use, a unique decision tree was created that offers
a streamlined user experience, while incorporating additional
information at every step. The app was well received by
urologists and won the BJUI award for Best Urology App in
2015, presented at the American Urological Association Annual
Meeting.
Starting with the total PSA value, a more complete assessment
is built based on supplementary information regarding a previous
negative prostate biopsy, DRE and TRUS findings, as well as
phi value. Multiple external validations and comparisons of the
RPCRC have shown that including more relevant information
increases predictive capability [9].
This app builds on the ubiquitous presence of mobile phones
to provide doctors and patients with a new way of using the
RPCRC. Moreover, it maintains the ERSPC’s original goal to
optimize prostate cancer screening, reducing unnecessary
prostate biopsies and preventing the overtreatment of indolent
prostate cancer while avoiding underdiagnosis. mHealth offers
the opportunity to change the paradigm of health services, and
prostate cancer, the second most common cancer worldwide,
must be included in that effort [1].
In addition, it was designed and developed from day 1 by a
multidisciplinary team, which included not only urologists but
also other health care professionals, which has been shown to
influence significantly the number of app downloads [36].
The strength of the RPCRC app is its development based on
high-quality health information extracted from various published
studies that validate the outcome of ERSPC risk calculator in
multiple cohorts.
The IBM Computer Usability Satisfaction Questionnaire allowed
the authors to obtain quantitative information regarding the app
usability, which offered strong measures of usability. Moreover,
taking into consideration that tests with only 5 participants are
able to uncover 85% of usability issues, we believe most
usability issues would be identified in this study, which included
92 users [37].
Limitations
In this study, we only discuss the development of the iOS app,
but further studies are under way to replicate this for other
mobile platforms. Only medical students and health care
professionals took part in the usability testing, which may
represent a selection bias. In the near future, a similar evaluation
will be done for patients.
Conclusions
We created a scientifically valid and convenient mobile app for
the RPCRC. The RPCRC has been designed to help patients
and to assist health care professionals in the decision-making
process. The app was found to be easy to use and, therefore,
can be useful in the daily management of patients. The RPCRC
app can be used in a clinical setting to better stratify the risk of
prostate cancer, avoiding unnecessary biopsies and,
consequently, reducing overdiagnosis and overtreatment.
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